Irritable bowel syndrome: An update on therapeutic modalities

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1211-1222

  Farhadi, A ^a   Bruninga, K ^a   Fields, J ^a   Keshavarzian, A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CNS; Complementary alternative medicine; Emotional stress; GI motility treatments; GI sensory treatments

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALOSETRON; ANTIDIARRHEAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DILTIAZEM; DOMEPRIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; HERBACEOUS AGENT; IMIPRAMINE; LOPERAMIDE; LOXIGLUMIDE; MEBEVERINE; ONDANSETRON; PEPPERMINT OIL; PLACEBO; PROKINETIC AGENT; PRUCALOPRIDE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN DERIVATIVE; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUPUNCTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST OF ILLNESS; DIET THERAPY; DIETARY FIBER; DOUBLE BLIND PROCEDURE; EMOTION; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HEALTH EDUCATION; HEART ARRHYTHMIA; HERBAL MEDICINE; HOMEOPATHY; HUMAN; IRRITABLE COLON; MALE; META ANALYSIS; MODULATION; NONHUMAN; OUTPATIENT DEPARTMENT; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICIAN; POPULATION; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SENSATION; SYMPTOM; VISCERA;

ACUPUNCTURE THERAPY; CENTRAL NERVOUS SYSTEM AGENTS; COLONIC DISEASES, FUNCTIONAL; DIETARY FIBER; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; PHYTOTHERAPY;

EID: 0034936729     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1211     Document Type: Review

References (126)

1. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
2. Irritable bowel syndrome in general practice: Prevalence, characteristics, and referral
3. Functional bowel disorders in apparently healthy people
4. Irritable bowel syndrome: Definition, diagnosis and epidemiology
5. Irritable bowel syndrome in the general population
6. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome
7. Medical costs in community subjects with irritable bowel syndrome
8. Impact of functional dyspepsia on quality of life
9. Controlled treatment trials in the irritable bowel syndrome: A critique
10. Towards positive diagnosis of the irritable bowel
11. Evaluation of Manning's criteria in the diagnosis of irritable bowel syndrome
12. Manning criteria in irritable bowel syndrome: Its diagnostic significance
13. The Rome criteria process: Diagnosis and legitimization of irritable bowel syndrome
14. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
15. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon
16. Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations
17. Visceral afferent stimulation-evoked changes in the release of peptides into the parabrachial nucleus in vivo
18. Brain-gut interactions: Implications for newer therapy
19. Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction
20. Psychiatric illness and the irritable bowel syndrome. Practical implications for the primary physician
21. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
22. Psychosocial factors in the irritable bowel syndrome: A multivariate study of patients and nonpatients with irritable bowel syndrome
23. Terminal ileal mucosal mast cells in irritable bowel syndrome
24. Increased mast cells in the irritable bowel syndrome
25. Effects of inflammatory mediators on gut sensitivity
26. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome
27. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome
28. Colonic tone and motility in patients with irritable bowel syndrome
29. Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features
30. Ambulatory small intestinal motility in 'diarrhea'-predominant irritable bowel syndrome
31. Disturbed motilin and cholecystokinin release in the irritable bowel syndrome
32. Principles of applied neurogastroenterology: Physiology/motility-sensation
33. Evidence for two distinct perceptual alterations in irritable bowel syndrome
34. Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome
35. Pathobiology of visceral pain: Molecular mechanisms and therapeutic implications IV. Visceral afferent contributions to the pathobiology of visceral pain
36. Basic and clinical aspects of visceral hyperalgesia
37. Recent and forgotten aspects of visceral pain
38. Stress, inflammation and the irritable bowel syndrome
39. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
40. The fecal microbial population in the irritable bowel syndrome
41. Abnormal colonic fermentation in irritable bowel syndrome
42. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome
43. Brain-gut interactions: Implications for newer therapy
44. Comparison of the effects of psyllium and wheat bran on gastrointestinal transit time and stool characteristics
45. Comparison of diet composition in women with and without functional bowel disorder
46. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
47. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
48. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
49. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome
50. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome
51. Otilonium bromide: A selective spasmolytic for the gastrointestinal tract
52. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome
53. Effect of oral nicardipine on anorectal function in normal human volunteers and patients with irritable bowel syndrome
54. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial
55. Diltiazem in the treatment of the irritable bowel syndrome
56. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial
57. Peppermint oil for irritable bowel syndrome: A critical review and metaanalysis
58. Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome
59. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
60. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome
61. Loperamide treatment of the irritable bowel syndrome
62. Loperamide in treatment of irritable bowel syndrome: A double-blind placebo controlled study
63. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency
64. Management of the Irritable Bowel Syndrome
65. Use of the peripheral dopamine antagonist, domperidone, in the management of gastrointestinal symptoms in patients with the irritable bowel syndrome
66. Oral domperidone: Double blind comparison with placebo in the irritable bowel syndrome
67. Domperidone treatment in the irritable bowel syndrome
68. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: A placebo-controlled study of cisapride
69. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
70. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation
71. Serotonin: A mediator of the brain-gut connection
72. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
73. Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-IBS)
74. Pharmacology and clinical experience with alosetron
75. The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat
76. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
77. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
78. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
79. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3-receptor antagonist
80. Drug for irritable bowel syndrome taken off the market
81. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism
82. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)
83. A review of its pharmacology and preliminary clinical findings in novel applications
84. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity
85. Reduction of rectal sensitivity and post-prandial motility by granistron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome
86. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
87. Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist
88. Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome
89. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: Results of two double-blind, placebo-controlled trials
90. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome
91. Efficacy of peripheral kappa agonist, fedotozine, vs. placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
92. Pharmacology and clinical experience with fedotozine
93. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids
94. Trimebutine: Mechanism of action, effects on gastrointestinal function and clinical results
95. Lack of effect of naloxone in the irritable bowel syndrome
96. Adrenergic modulation of human colonic motor and sensory function
97. Towards identifying optimal doses for α-2 adrenergic modulation of colonic and rectal motor and sensory function
98. Double-blind study of an alpha 2 agonist in the treatment of the irritable bowel syndrome
99. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone
100. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients
101. Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome
102. Some of the challenges in drug development for irritable bowel syndrome
103. Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats
104. Responses of rat spinal neurons to distension of inflamed colon: Role of tachykinin NK2 receptors
105. Neurotrophins: Peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity
106. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions
107. Axonal transport of neurotrophins by visceral afferent and efferent neurons of the vagus nerve of the rat
108. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans
109. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity
110. Symptom relief with amitriptyline in the irritable bowel syndrome
111. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis
112. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans
113. Symptom relief with amitriptyline in the irritable bowel syndrome
114. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome
115. Paroxetine and irritable bowel syndrome
116. Antidepressant therapy in 138 patients with irritable bowel syndrome: A five-year clinical experience
117. Treatment of irritable bowel syndrome with Lacterol Fort: A randomized, double-blind, crossover trial
118. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice
119. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome
120. Double-blind crossover trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance
121. Health-care-seeking behaviors related to bowel complaints. Hispanics versus non-Hispanic whites
122. Comparative studies of the effectiveness of brief psychotherapy, acupuncture and papaverin therapy in patients with irritable bowel syndrome
123. The role of acupuncture in the treatment of irritable bowel syndrome: A pilot study
124. Treatment of irritable colon with the food additive
125. Irritable bowel syndrome: Therapeutic evaluation of indigenous drugs
126. Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial